AZD 8931

AZD 8931

CAT N°: 24196
Price:

From 66.00 56.10

AZD 8931 is a reversible inhibitor of the receptor tyrosine kinases ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3 (IC50s = 4, 3, and 4 nM, respectively, for autophosphorylation).{42033} In vitro, AZD 8931 (0.01, 0.1, and 1 µM) suppresses cell growth and induces apoptosis in SUM149 and FC-IBC-02 human breast cancer cell lines.{42034} In vivo, AZD 8931 (6.25-50 mg/kg) inhibits tumor growth in BT474c, Calu-3, LoVo, FaDu, and PC-9 mouse xenograft models.{42033} When administered in combination with paclitaxel (Item No. 10461), AZD 8931 inhibits inflammatory breast cancer tumor growth in a mouse xenograft model when administered at a dose of 25 mg/kg per day.{42034}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-methyl-1-piperidineacetamide
  • Correlated keywords
    • AZD8931 Sapatinib Erb-B1 B3 B2 HER-2 3 SUM-149 FCIBC-02 FCIBC02 BT-474c BT474-c Calu3 PC9 auto-phosphorylation
  • Product Overview:
    AZD 8931 is a reversible inhibitor of the receptor tyrosine kinases ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3 (IC50s = 4, 3, and 4 nM, respectively, for autophosphorylation).{42033} In vitro, AZD 8931 (0.01, 0.1, and 1 µM) suppresses cell growth and induces apoptosis in SUM149 and FC-IBC-02 human breast cancer cell lines.{42034} In vivo, AZD 8931 (6.25-50 mg/kg) inhibits tumor growth in BT474c, Calu-3, LoVo, FaDu, and PC-9 mouse xenograft models.{42033} When administered in combination with paclitaxel (Item No. 10461), AZD 8931 inhibits inflammatory breast cancer tumor growth in a mouse xenograft model when administered at a dose of 25 mg/kg per day.{42034}

We also advise you